Aquarius Population Health
Transforming health, for everyone
At Aquarius we understand the importance of developing a love of learning from an early age. The education we receive at school creates the foundation for later studies and professional development. That’s why we decided to work pro bono with Homework Hotline, an educational charity that provides free after school tutoring to any school aged child in the state of Tennessee, USA.
Continue reading
We’re pleased to have welcomed two new members of the Aquarius team since moving to our new office in Tileyard in 2018.
Georgie Weston joined the team in October as an Associate, having recently completed her Master of Public Health at the London School of Hygiene and Tropical Medicine, awarded with Distinction. Georgie has experience working with a range of organisations, including the WHO, health charities, and large pharmaceutical companies where she worked within communications and marketing strategy.
Continue reading
At Aquarius Population Health we understand the importance of keeping our team well hydrated to support their health and top performance throughout the day. As a result, we decided to invest in a water-cooler and water-heater from AquAid.
Continue reading
Aquarius were part of a recent feasibility trial looking at whether provision of a same day test and treatment service for chlamydia in further education colleges increased uptake of chlamydia testing and treatment. The results of the trial were published this week in Clinical Microbiology and Infection and are available online.
New point-of-care (POC) tests are currently being developed which can be used in clinic to simultaneously test for multiple sexually transmitted infections (STIs). In work now published online in BMJ Open, we developed a model to compare three possible strategies for POC STI testing with the current practice of microscopy and lab-based testing. The three strategies were: 1) a dual test for chlamydia and gonorrhoea; 2) a triple test which also tests for M. genitalium, and 3) a quadruple test which also tested for trichomoniasis. The model examined the overall costs, patient benefits and cost-effectiveness of these strategies. The full results of the economic evaluation including the article and supplementary material are available online.
An article authored by Aquarius was published today on the British In Vitro Diagnostics Association (BIVDA) website. The article commissioned jointly by BIVDA and Innovate UK suggests that the NHS could save over £6.9 billion in 5 years by making better use of diagnostic tests already on the market. These savings could have a huge impact in reducing the annual NHS shortfall, which is expected to be £20 billion by 2022.
At Aquarius, we love an opportunity to learn new skills and work together as a team to produce something we’re proud of. Our team away day was no exception. In an 800-acre forest in the depths of West Sussex, we spent the day in our outdoor gear learning some bush craft and how we can achieve our business strategy in the coming year.
The winter flu season brings added pressure to emergency and acute hospital services. In the UK, children and infants account for more than a third of flu related hospital admissions since flu and respiratory syncytial viruses (RSV) can be particularly severe in children, particularly those with existing conditions such as asthma.
In our recent paper published, we report the results of a real-world evaluation conducted in a busy children’s hospital in central London. We assessed the impact and economic benefits of using a 90-minute point-of-care (POC) assay to test for influenza and RSV in children and infants admitted to hospital. This was done by comparing data collected from an acute paediatric ward during one flu season, when standard laboratory testing was used, with data collected from the same ward in the subsequent flu season, when the POC test was in use.
In January, Elisabeth, Mike and I attended the European MedTech Forum in Brussels, a three-day annual event which brings together key players from the world of in-vitro diagnostics and medical devices. We enjoyed engaging with senior decision-makers from across Europe and beyond, including representatives from small start-ups to large multinationals.
In the latest episode of the BBC’s show, “Trust me, I’m a Doctor”, an innovative new product called Magseed is being trialled to improve surgery for women with breast cancer. A tiny magnetic seed is being used to transform how cancerous tissue is localised so that it can be removed, rather than using traditional guide wires. This helps the surgeons pinpoint exactly where they need to operate, and which angle is the best to approach the tumour. Much smaller tumours are currently being detected through the breast cancer screening programme, which are more difficult to find during surgery using guide wires.